Jump to content


Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

EU Funded

2D-BioPAD logo


2D-BioPAD is pioneering a graphene-based Point of-Care (PoC) In-Vitro Diagnostics (IVD) system for early Alzheimer’s Disease (AD) detection. This non-invasive solution, using 2D materials, can identify and quantify up to 5 AD biomarkers in real time. Clinical pilot studies in Finland, Greece, and Germany aim to demonstrate its impact, with a focus on safety, ethics, and seamless integration into primary healthcare settings.


Project Partners


Learn more about our consortium here.


Project Clinical Centres

The 2D-BioPAD system and its impact will be demonstrated in 3 clinical centres in Europe - University of Eastern Finland, GAADRD, and ZI - under two clinical pilot studies.

Each centre will provide access to existing diagnosed biological samples, including supporting information such as demographics, comorbidities, cognitive assessments, as well as other valuable health records towards allowing not only the effective development of the 2D-BioPAD devices, but also its user-centred evaluation and validation. Read more here.

Project Technologies

The 2D-BioPAD aims to achieve its goal by combining various technologies and methodologies, including graphene-based biosensing, aptamers, magnetic nanoparticles, microfluidics, and artificial intelligence. Read more here.

Follow us on:


Related articles

doctor with graphene solutions MUNASET
MUNASET / Biomedical / Our project

MUNASET: A new Horizon Europe project kicked off

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.

By Graphene Flagship / 06 December 2023
Show all news